Farapulse, Inc. appears in FDA premarket approval records as the applicant for P230030, a Class 3 device under product code QZI, described generically as a percutaneous cardiac ablation catheter for treatment of atrial fibrillation with irreversible electroporation. The filing address listed is 3715 Haven Ave., Suite 110, Menlo Park, CA 94025, which is a correspondence address in the filing rather than a verified headquarters. The linked FDA records document the original approval and two later supplements, each tied to a distinct submission number and decision date. [1][2][3]
Documented system and components
The trade name recorded for P230030 is the FARAPULSE Pulsed Field Ablation System, listing the FARAWAVE Pulsed Field Ablation Catheter, the FARASTAR Catheter Connection Cable, the FARASTAR Pulsed Field Ablation Generator, and the FARASTAR Recording System Module among its components. A Summary of Safety and Effectiveness Data document adds the FARAWAVE NAV and FARAPOINT catheters, the FARASTAR Mapping System Module, stimulation module cables, and EGM and ECG cabling to the trade-name listing. [3][7][10]
The recorded indication language covers isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic paroxysmal atrial fibrillation. Separate component statements describe the Recording System Module as a filtering and protection unit connected between the patient and attached recording or ECG systems and as an interface for cardiac stimulation output, and the Catheter Connection Cable as intended for use with a FARAPULSE catheter during an electrophysiology procedure for cardiac tissue ablation. [3]
Original approval and supplement activity
The original P230030 approval carries a decision date of January 30, 2024. The SSED states that CDRH issued an approval order on that date and describes an ADVENT post-approval study as a prospective, non-randomized, multicenter, single-arm study to evaluate long-term effectiveness and safety of the system. [3][10]
Supplement S024, received June 30, 2026 and decided September 4, 2026, was approved for FARASTAR PFA Generator Software 4.5.3/4.6.3, a FARASTAR Foot Switch, and updates to the FARASTAR System Instructions for Use, under the supplement reason change in design, components, specifications or material. Supplement S025, received September 14, 2026 and decided October 2, 2026, is a 30-day notice for a process change involving manufacturer, sterilizer, packager or supplier, with an additional supplier location site noted. [1][2]
What the collection shows
The supplied collection holds three linked PMA records as of the snapshot date, all on the PMA pathway: two approvals and one 30-day notice. The smaller record sample of three entries shows the same split of two approvals and one 30-day notice. These counts describe the supplied filings only and are not measures of total portfolio, sales or safety performance. [1][2][3]
The advisory committee recorded for these filings is Cardiovascular, and the expedited review flag is recorded as N on both supplements. No recall records appear in the supplied sample. The records do not establish any parent company, brand ownership, website, customer list, certification or commercial availability, and none should be inferred from the applicant name alone. [1][2]


